

Joint Working Executive Summary -

Celgene website declaration

All joint working agreements must be certified in accordance with Clause 14.1

JW Partner(s)	<p>NHS Greater Glasgow & Clyde</p> <p>Novartis Pharmaceuticals</p> <p>Celgene Limited</p>
Project period	12 months
Project Name	NHS Greater Glasgow & Clyde Molecular Diagnostic Pathway Development
<p>Joint working project summary: (sufficient to give a reader a clear understanding of the work to be undertaken)</p>	<p>This Joint Working Project aims to introduce new molecular techniques into routine clinical practice. The project aims at achieving the following objectives:</p> <ol style="list-style-type: none"> 1. Identify companion or stand-alone diagnostics for introduction in patient pathways across Scotland and to inform on the current Scottish process to approve companion or stand-alone diagnostics for the relevant medicines 2. Develop pathways across Scotland incorporating: <ul style="list-style-type: none"> - relevant companion or stand-alone diagnostics as identified in the course of the Project; efficient and effective sequential testing strategies such as the introduction of Next Generation Sequencing (“NGS”) and other novel technologies to routine practice 3. Provide the regional molecular pathology laboratories in Scotland with means of test validation for diagnostic tools to support new pathways by sharing relevant information developed in the course of the Project; 4. Highlight the impact on patient access to medicines and companion diagnostics supported by the process developed in the course of the Project: 5. Develop protocols which support genetic testing for entry of patients in clinical trials, in collaboration with WoSCAN clinicians and the NHS GG&C Clinical trials unit. 6. Educate the wider community of academia, NHS and pharmaceutical industry on the benefits of increasing access to medicines’ relevant diagnostics tests for patients and show the value of stakeholder’s collaboration in this project to gain support to further develop the service established in the course of the Project.
<p>Expected patient outcomes for this project</p>	<p>The Project extension shall aim at furthering and consolidating the objectives already achieved through the Project in the previous year, namely, improving patient outcomes by incorporating a prognostic and diagnostic tool in the relevant patient pathways across Scotland for specific drugs to be identified by optimising the use of medicines in suitable patients.</p>

Start Date & Duration	Project start date: January 2015 Amendment agreement: Dec 2016 Project end date: Dec 2017
--------------------------	---

Date of preparation May 2017 UK-CELG170108